Mordecai Alfred Winborne has filed an amendment to his previous Schedule 13D, reporting a decrease in his beneficial ownership of shares in the PRIMECAP Odyssey Discovery ETF (POMG). This change is significant as it reflects a strategic adjustment in his investment portfolio.
Winborne's latest filing, dated November 2, 2026, indicates that he now holds 50,000 shares of the ETF, accounting for approximately 2.4% of the total outstanding shares. This marks a notable decrease as he has fallen below the 5% ownership threshold, which often triggers additional reporting requirements.
Background
Mordecai Alfred Winborne, identified by CIK 0002158621, is an individual investor who has been actively managing his holdings in various funds. The PRIMECAP Odyssey Funds, which includes the PRIMECAP Odyssey Discovery ETF, is incorporated in Delaware and has been a significant player in the exchange-traded fund (ETF) market.
The recent filings include a Schedule 13D/A on November 2, 2026, and an initial Schedule 13D on October 26, 2026. These documents provide insights into Winborne's investment activities and changes in his ownership stakes.
What the Filing Says
The filing states, "This Amendment No. 1 to Schedule 13D relates to the common shares ('Shares') of PRIMECAP Odyssey Discovery ETF ('POMG'), and amends the initial statement on Schedule 13D filed by the undersigned on October 26, 2026." Winborne's filing highlights a decrease in his beneficial ownership due to the total outstanding shares of POMG being reported at 2,060,000 as of October 30, 2026.
Impact
This decrease in ownership may affect various stakeholders, including other investors in the ETF space, as it could signal a shift in market sentiment or investment strategy. Winborne's actions might influence the behavior of other investors and funds in the competitive ETF landscape.
What's Next
The filing does not specify what actions will follow this amendment. Investors and market analysts will be keen to observe any further developments regarding Winborne's investment strategy or additional filings related to his holdings.
Read Next
Christine Ring Reports Stock Transactions at Nurix Therapeutics
Myriad Genetics officer Jennifer Fox acquires 39,370 shares
FOXO Technologies Acquires Stake in Ludwig Enterprises, Inc.
Fortive Corp's Mulhall Reports Stock Transactions in SEC Filing
Fortive Corp Chief Legal Officer Reports Stock Transactions
BHAV Partners II reports ownership change with 225,000 shares







